Literature DB >> 28983463

The "liquid biopsy" in non-small cell lung cancer - not quite ready for prime time use.

Angel Qin1, Nithya Ramnath1,2.   

Abstract

Entities:  

Year:  2016        PMID： 28983463      PMCID： PMC5626003          DOI： 10.21037/tcr.2016.10.29

Source DB:  PubMed          Journal:  Transl Cancer Res        ISSN： 2218-676X            Impact factor:   1.241


× No keyword cloud information.
  12 in total

1.  Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer.

Authors:  Adrian G Sacher; Cloud Paweletz; Suzanne E Dahlberg; Ryan S Alden; Allison O'Connell; Nora Feeney; Stacy L Mach; Pasi A Jänne; Geoffrey R Oxnard
Journal:  JAMA Oncol       Date:  2016-08-01       Impact factor: 31.777

Review 2.  Liquid Biopsies in Oncology and the Current Regulatory Landscape.

Authors:  Lindsay N Strotman; Lori M Millner; Roland Valdes; Mark W Linder
Journal:  Mol Diagn Ther       Date:  2016-10       Impact factor: 4.074

Review 3.  Scientific Advances in Lung Cancer 2015.

Authors:  Anne S Tsao; Giorgio V Scagliotti; Paul A Bunn; David P Carbone; Graham W Warren; Chunxue Bai; Harry J de Koning; A Uraujh Yousaf-Khan; Annette McWilliams; Ming Sound Tsao; Prasad S Adusumilli; Ramón Rami-Porta; Hisao Asamura; Paul E Van Schil; Gail E Darling; Suresh S Ramalingam; Daniel R Gomez; Kenneth E Rosenzweig; Stefan Zimmermann; Solange Peters; Sai-Hong Ignatius Ou; Thanyanan Reungwetwattana; Pasi A Jänne; Tony S Mok; Heather A Wakelee; Robert Pirker; Julien Mazières; Julie R Brahmer; Yang Zhou; Roy S Herbst; Vassiliki A Papadimitrakopoulou; Mary W Redman; Murry W Wynes; David R Gandara; Ronan J Kelly; Fred R Hirsch; Harvey I Pass
Journal:  J Thorac Oncol       Date:  2016-03-22       Impact factor: 15.609

4.  Liquid Biopsy in Lung Cancer: A Perspective From Members of the Pulmonary Pathology Society.

Authors:  Lynette M Sholl; Dara L Aisner; Timothy Craig Allen; Mary Beth Beasley; Philip T Cagle; Vera L Capelozzi; Sanja Dacic; Lida P Hariri; Keith M Kerr; Sylvie Lantuejoul; Mari Mino-Kenudson; Kirtee Raparia; Natasha Rekhtman; Sinchita Roy-Chowdhuri; Eric Thunnissen; Ming Tsao; Marina Vivero; Yasushi Yatabe
Journal:  Arch Pathol Lab Med       Date:  2016-05-19       Impact factor: 5.534

5.  A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial.

Authors:  Masahiko Yanagita; Amanda J Redig; Cloud P Paweletz; Suzanne E Dahlberg; Allison O'Connell; Nora Feeney; Myriam Taibi; David Boucher; Geoffrey R Oxnard; Bruce E Johnson; Daniel B Costa; David M Jackman; Pasi A Jänne
Journal:  Clin Cancer Res       Date:  2016-06-08       Impact factor: 12.531

Review 6.  Overcoming drug resistance to receptor tyrosine kinase inhibitors: Learning from lung cancer.

Authors:  Michihiko Kuwano; Kahori Sonoda; Yuichi Murakami; Kosuke Watari; Mayumi Ono
Journal:  Pharmacol Ther       Date:  2016-03-18       Impact factor: 12.310

7.  Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer.

Authors:  Geoffrey R Oxnard; Kenneth S Thress; Ryan S Alden; Rachael Lawrance; Cloud P Paweletz; Mireille Cantarini; James Chih-Hsin Yang; J Carl Barrett; Pasi A Jänne
Journal:  J Clin Oncol       Date:  2016-06-27       Impact factor: 44.544

8.  High level of chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung cancer.

Authors:  E Pailler; N Auger; C R Lindsay; P Vielh; A Islas-Morris-Hernandez; I Borget; M Ngo-Camus; D Planchard; J-C Soria; B Besse; F Farace
Journal:  Ann Oncol       Date:  2015-04-06       Impact factor: 32.976

9.  Evaluation of Circulating Tumor Cells and Related Events as Prognostic Factors and Surrogate Biomarkers in Advanced NSCLC Patients Receiving First-Line Systemic Treatment.

Authors:  Laura Muinelo-Romay; Maria Vieito; Alicia Abalo; Marta Alonso Nocelo; Francisco Barón; Urbano Anido; Elena Brozos; Francisca Vázquez; Santiago Aguín; Miguel Abal; Rafael López López
Journal:  Cancers (Basel)       Date:  2014-01-21       Impact factor: 6.639

10.  Detection of mutations in EGFR in circulating lung-cancer cells.

Authors:  Shyamala Maheswaran; Lecia V Sequist; Sunitha Nagrath; Lindsey Ulkus; Brian Brannigan; Chey V Collura; Elizabeth Inserra; Sven Diederichs; A John Iafrate; Daphne W Bell; Subba Digumarthy; Alona Muzikansky; Daniel Irimia; Jeffrey Settleman; Ronald G Tompkins; Thomas J Lynch; Mehmet Toner; Daniel A Haber
Journal:  N Engl J Med       Date:  2008-07-02       Impact factor: 91.245
View more
  2 in total

1.  Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib.

Authors:  Maximilian J Hochmair; Anna Buder; Sophia Schwab; Otto C Burghuber; Helmut Prosch; Wolfgang Hilbe; Agnieszka Cseh; Richard Fritz; Martin Filipits
Journal:  Target Oncol       Date:  2019-02       Impact factor: 4.493

Review 2.  Integration of liquid biopsy and pharmacogenomics for precision therapy of EGFR mutant and resistant lung cancers.

Authors:  Jill Kolesar; Spencer Peh; Levin Thomas; Gayathri Baburaj; Nayonika Mukherjee; Raveena Kantamneni; Shirley Lewis; Ananth Pai; Karthik S Udupa; Naveena Kumar An; Vivek M Rangnekar; Mahadev Rao
Journal:  Mol Cancer       Date:  2022-02-24       Impact factor: 27.401
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.